多发性骨髓瘤-话题@MedSci

#多发性骨髓瘤#

50篇内容 | 4233人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1198395, encodeId=8ea4119839527, content=<a href='/topic/show?id=85fa10446166' target=_blank style='color:#2F92EE;'>#西达基奥仑赛#</a><a href='/topic/show?id=3e26e794600' target=_blank style='color:#2F92EE;'>#细胞治疗#</a>，这个厉害，<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>就成为了慢病了！总缓解率(ORR)高达98%(95%CI：92.7-99.7)，78%的患者获得了严格的完全反应(sCR，95%CI：68.8-86.1)。在18个月的中位随访时间中，中位缓解持续时间(DOR)为21.8个月(95% CI，21.8-无法预估)。估计随着随访时间延长，未来可能会更长！大量患者获得长期生存. 目前在美国定价为46.5万美元，还算便宜吧。在国内未来定位应该在80万人民币左右，这样就是平民价格了。, objectTitle=FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市, objectType=article, longId=299876, objectId=e4402998e658, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220228/08994fa1326a43f3a6325a7847e80f38.jpg, objectUrl=/article/show_article.do?id=e4402998e658, replyNumber=0, likeNumber=137, createdTime=2022-03-01, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4402998e658, moduleTitle=FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4402998e658)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1196667, encodeId=7810119666ec5, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>学习, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=65, createdTime=2022-02-24, rootId=0, userName=ms9000000046672090, userId=510d5710114, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1180920, encodeId=76341180920a7, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>学习, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=64, createdTime=2022-01-05, rootId=0, userName=时也, userId=438a5513819, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1180919, encodeId=27b6118091951, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>学习, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=65, createdTime=2022-01-05, rootId=0, userName=时也, userId=438a5513819, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1060799, encodeId=623e1060e99c9, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>达雷妥尤单抗联合来那度胺和地塞米松相比单用来那度胺和地塞米松可延长不适合进行干细胞移植的新确诊的多发性骨髓瘤患者的总生存期和无进展生存期。无新的安全性事件发生。该研究结果支持在一线使用达雷妥尤单抗+来那度胺和地塞米松治疗不适合移植的多发性骨髓瘤患者。, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=93, createdTime=2021-10-15, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=969772, encodeId=7868969e7234, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>CAR-T治疗多发性骨髓瘤会不会进一步加深MM的缓解深度, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=1, likeNumber=116, createdTime=2021-05-31, rootId=0, userName=14674335m17暂无昵称, userId=fa565140002, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=955330, encodeId=14d29553309b, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>哪里可以看到相关最新资讯, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=2, likeNumber=118, createdTime=2021-04-08, rootId=0, userName=yqbs11, userId=cfc12612169, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1053477, encodeId=c27a10534e7c6, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Clin Cancer Res：多发性骨髓瘤患者进行CAR T细胞治疗时可安全应用桥接放疗！, objectType=article, longId=217385, objectId=eeaf21e38561, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021920/1632150460555_2110107.JPG, objectUrl=/article/show_article.do?id=eeaf21e38561, replyNumber=0, likeNumber=121, createdTime=2021-09-21, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eeaf21e38561, moduleTitle=Clin Cancer Res：多发性骨髓瘤患者进行CAR T细胞治疗时可安全应用桥接放疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eeaf21e38561)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1052145, encodeId=9ba310521458c, content=<a href='/topic/show?id=5655104409bd' target=_blank style='color:#2F92EE;'>#达雷妥单抗#</a>维持治疗长达两年相比只是随访观察可显著降低<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>患者的疾病进展及死亡风险。, objectTitle=Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险, objectType=article, longId=217213, objectId=d65521e213ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021916/1631781391582_2110107.png, objectUrl=/article/show_article.do?id=d65521e213ea, replyNumber=0, likeNumber=102, createdTime=2021-09-16, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65521e213ea, moduleTitle=Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65521e213ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=999719, encodeId=e629999e1985, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>治疗进展, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=80, createdTime=2021-07-15, rootId=0, userName=ms4000000408264698, userId=e5185543565, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=966468, encodeId=d3a89664686b, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>多发性骨髓瘤的治疗需要进一步研究, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=101, createdTime=2021-05-18, rootId=0, userName=1903329706, userId=24324873661, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=964112, encodeId=e70e9641122a, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>多发性骨髓瘤与原发性淀粉样变性的区别, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=94, createdTime=2021-05-09, rootId=0, userName=hjhf, userId=88c54874945, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=953396, encodeId=0fb2953396f0, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Br J Cancer：ITGA6表达下调增强多发性骨髓瘤的侵袭作用并促进其发展为浆细胞白血病, objectType=article, longId=209342, objectId=a2c5209342f7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202142/1617293270011_2467676.PNG, objectUrl=/article/show_article.do?id=a2c5209342f7, replyNumber=0, likeNumber=158, createdTime=2021-04-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c5209342f7, moduleTitle=Br J Cancer：ITGA6表达下调增强多发性骨髓瘤的侵袭作用并促进其发展为浆细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2c5209342f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=924004, encodeId=e12692400494, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>多发性骨髓瘤的治疗策略有待进一步研究。, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=117, createdTime=2021-02-10, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=918816, encodeId=988f91881603, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, objectType=article, longId=206006, objectId=dea22060068e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021121/1611220870309_2110107.PNG, objectUrl=/article/show_article.do?id=dea22060068e, replyNumber=0, likeNumber=136, createdTime=2021-01-21, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea22060068e, moduleTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dea22060068e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=916410, encodeId=118891641093, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性, objectType=article, longId=205699, objectId=a34920569953, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/192.jpg, objectUrl=/article/show_article.do?id=a34920569953, replyNumber=0, likeNumber=1, createdTime=2021-01-14, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a34920569953, moduleTitle=Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a34920569953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=907272, encodeId=66e790e272ee, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Br J Cancer：逆转多发性骨髓瘤耐药性的替代策略, objectType=article, longId=204413, objectId=892c204413da, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201211/1607657347001_2467676.PNG, objectUrl=/article/show_article.do?id=892c204413da, replyNumber=0, likeNumber=164, createdTime=2020-12-12, rootId=0, userName=Nebula-Qin, userId=74c72110107, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=892c204413da, moduleTitle=Br J Cancer：逆转多发性骨髓瘤耐药性的替代策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=892c204413da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=907086, encodeId=678b90e086ba, content=<a href='/topic/show?id=f7934849981' target=_blank style='color:#2F92EE;'>#帕比司他#</a>用于<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性, objectType=article, longId=204420, objectId=fbc5204420da, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/rheumatoid_arthritis_s12_citrulline_test.jpg, objectUrl=/article/show_article.do?id=fbc5204420da, replyNumber=0, likeNumber=116, createdTime=2020-12-11, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbc5204420da, moduleTitle=Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbc5204420da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=905080, encodeId=d1aa90508001, content=<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a>及其衍生物已被广泛用于治疗恶性<a href='/topic/show?id=66c489335e5' target=_blank style='color:#2F92EE;'>#血液肿瘤#</a>和<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>，还用于很多实体瘤，如肝癌等，作为抗血管新生和免疫调节剂，作用不亚于贝伐单抗，对成人而言，安全性也是相当不错的。, objectTitle=沙利度胺可防止神经细胞死亡, objectType=article, longId=132282, objectId=ab43132282ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201803/20180313112158362.jpg, objectUrl=/article/show_article.do?id=ab43132282ae, replyNumber=0, likeNumber=204, createdTime=2020-12-05, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab43132282ae, moduleTitle=沙利度胺可防止神经细胞死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab43132282ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=881849, encodeId=27bb88184911, content=<a href='/topic/show?id=ff1c3654ebf' target=_blank style='color:#2F92EE;'>#卡非佐米#</a> 较 <a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a>虽然是新一代药物，但是对于<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>而言，要比出差异并不容易。因此，大家不必过度迷信新药，老药在联合方案中，往往仍然是不错的。, objectTitle=Lancet oncol：卡非佐米 vs 硼替佐米联合来那度胺+地塞米松治疗多发性骨髓瘤的疗效, objectType=article, longId=200125, objectId=9b81200125b7, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=9b81200125b7, replyNumber=0, likeNumber=195, createdTime=2020-09-01, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b81200125b7, moduleTitle=Lancet oncol：卡非佐米 vs 硼替佐米联合来那度胺+地塞米松治疗多发性骨髓瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b81200125b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多发性骨髓瘤

2020-05-29

医者仁者 (审核中...)

前往app查看评论内容

全文收起 #西达基奥仑赛##细胞治疗#，这个厉害，#多发性骨髓瘤#就成为了慢病了！总缓解率(ORR)高达98%(95%CI：92.7-99.7)，78%的患者获得了严格的完全反应(sCR，95%CI：68.8-86.1)。在18个月的中位随访时间中，中位缓解持续时间(DOR)为21.8个月(95% CI，21.8-无法预估)。估计随着随访时间延长，未来可能会更长！大量患者获得长期生存. 目前在美国定价为46.5万美元，还算便宜吧。在国内未来定位应该在80万人民币左右，这样就是平民价格了。

FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市

2022-03-01

ms9000000046672090 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#学习

2022-02-24

时也 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#学习

2022-01-05

时也 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#学习

2022-01-05

yangchou (审核中...)

前往app查看评论内容

#多发性骨髓瘤#达雷妥尤单抗联合来那度胺和地塞米松相比单用来那度胺和地塞米松可延长不适合进行干细胞移植的新确诊的多发性骨髓瘤患者的总生存期和无进展生存期。无新的安全性事件发生。该研究结果支持在一线使用达雷妥尤单抗+来那度胺和地塞米松治疗不适合移植的多发性骨髓瘤患者。

2021-10-15

14674335m17暂无昵称 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#CAR-T治疗多发性骨髓瘤会不会进一步加深MM的缓解深度

2021-05-31

yqbs11 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#哪里可以看到相关最新资讯

2021-04-08

病毒猎手 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Clin Cancer Res：多发性骨髓瘤患者进行CAR T细胞治疗时可安全应用桥接放疗！

2021-09-21

病毒猎手 (审核中...)

前往app查看评论内容

#达雷妥单抗#维持治疗长达两年相比只是随访观察可显著降低#多发性骨髓瘤#患者的疾病进展及死亡风险。

Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险

2021-09-16

ms4000000408264698 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#治疗进展

2021-07-15

1903329706 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#多发性骨髓瘤的治疗需要进一步研究

2021-05-18

hjhf (审核中...)

前往app查看评论内容

#多发性骨髓瘤#多发性骨髓瘤与原发性淀粉样变性的区别

2021-05-09

智者为医08 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Br J Cancer：ITGA6表达下调增强多发性骨髓瘤的侵袭作用并促进其发展为浆细胞白血病

2021-04-02

yangchou (审核中...)

前往app查看评论内容

#多发性骨髓瘤#多发性骨髓瘤的治疗策略有待进一步研究。

2021-02-10

zb1235672 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤

2021-01-21

zb1235672 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性

2021-01-14

Nebula-Qin (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Br J Cancer：逆转多发性骨髓瘤耐药性的替代策略

2020-12-12

lifefamily (审核中...)

前往app查看评论内容

#帕比司他#用于#多发性骨髓瘤#

Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性

2020-12-11

lifefamily (审核中...)

前往app查看评论内容

#沙利度胺#及其衍生物已被广泛用于治疗恶性#血液肿瘤#和#多发性骨髓瘤#，还用于很多实体瘤，如肝癌等，作为抗血管新生和免疫调节剂，作用不亚于贝伐单抗，对成人而言，安全性也是相当不错的。

沙利度胺可防止神经细胞死亡

2020-12-05

lovetcm (审核中...)

前往app查看评论内容

#卡非佐米# 较 #硼替佐米#虽然是新一代药物，但是对于#多发性骨髓瘤#而言，要比出差异并不容易。因此，大家不必过度迷信新药，老药在联合方案中，往往仍然是不错的。

Lancet oncol：卡非佐米 vs 硼替佐米联合来那度胺+地塞米松治疗多发性骨髓瘤的疗效

2020-09-01

科室
- - 订阅+
  - 更多科室
工具
服务